The early diagnosis method of Parkinson's disease

Parkinson's disease has no specific symptoms and thus is difficult to be diagnosed in time. When patients with mobility disorders can be diagnosed, the nerve cells have got irreversible damage, and the effect of drug treatment is quite limited. Researchers at the University of Würzburg and the University of Fort Worth have made significant progress in this research through recombinant mouse proteins and have succeeded in discovering that the risk of Parkinson's disease can be diagnosed by skin tests, which is earlier than the current diagnosis.

Scientists have examined the skin of patients without Parkinson's symptoms and found α-synuclein specific to Parkinson's patients in their nerve endings. This protein, which is characteristic of Parkinson's disease, is no stranger to the industry, but it is often determined in the patient's brain only after the patient has died.

Now the German scientists in the patient before the onset or in the early sick through a small five-mm skin biopsy can diagnose Parkinson's disease, so that the nerve can be destroyed before the patient can be targeted and effective treatment. By the way, Flarebio provides you with high-quality recombinant proteins and antibodies like recombinant TLR2.